Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30 sept. 2019 17h00 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Announces Presentations at IDWeek 2019
26 sept. 2019 08h30 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Announces Second Quarter 2019 Operating Results and Provides Pipeline Update
08 août 2019 16h10 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Announces $5.9 Million Award from U.S. Department of Defense to Further Clinical Development of SPR206
16 juil. 2019 08h00 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., July 16, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics to Present Data for All Pipeline Programs at the ASM Microbe 2019 Conference
17 juin 2019 08h30 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., June 17, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Announces $10 Million Registered Direct Offering of Common Stock
13 juin 2019 08h00 HE
|
Spero Therapeutics, Inc.
Novo Holdings A/S through its Novo REPAIR Impact Fund to Invest Up to $10 million Net Proceeds to Advance Spero’s SPR720 CAMBRIDGE, Mass., June 13, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics,...
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31 mai 2019 17h00 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., May 31, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Announces First Quarter 2019 Operating Results and Provides Pipeline Review
09 mai 2019 16h10 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 mai 2019 08h00 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., May 01, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Highlights SPR994 Data at the 29th European Congress of Clinical Microbiology and Infectious Diseases
08 avr. 2019 08h30 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., April 08, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...